Daewoong Pharmaceutical Co. Ltd. and Daewoong Therapeutics Inc. achieved 80% relative bioavailability of semaglutide via a self-developed microneedle patch in a pilot human pharmacokinetic study. This injectable-free weekly patch substantially exceeds bioavailability rates compared to other transdermal or oral formulations. The innovation could improve patient compliance and relieve injection-related burdens for conditions treated with semaglutide, such as diabetes and obesity. Further development and clinical trials will evaluate therapeutic efficacy.